Drug Profile
Influenza A virus vaccine H3N2 - Sanofi
Alternative Names: H3N2v vaccine - Sanofi; Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203 vaccine - Sanofi; Monovalent inactivated influenza H3N2 variant vaccine - SanofiLatest Information Update: 04 Apr 2022
Price :
$50
*
At a glance
- Originator sanofi pasteur
- Developer National Institute of Allergy and Infectious Diseases; Sanofi
- Class Influenza A vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Influenza A virus H3N2 subtype
Most Recent Events
- 23 Mar 2017 Phase-II development for Influenza-A virus H3N2 subtype (Prevention) is ongoing in USA (IM)
- 29 Sep 2016 National Institute of Allergy and Infectious Diseases plans a phase II trial for Influenza-A virus H3N2 subtype (Prevention, In adults) in USA (IM) (NCT02921997)
- 21 May 2014 NIAID plans a phase II trial for Influenza-A virus H3N2 subtype (prevention in infants, children and adolescents) in USA (NCT02100436)